Post-traumatic stress disorder is one of the most debilitating and complex conditions in mental health. It can develop following a wide range of traumatic experiences, from combat and assault to accidents, childhood abuse, sudden loss, and medical emergencies. For many people, standard treatments for PTSD, including trauma-focused psychotherapy and medication, produce meaningful improvement. But a significant proportion of people with PTSD continue to experience severe symptoms despite adequate treatment. For this group, emerging evidence suggests that ketamine may represent an important new option.
This blog reviews what the research currently shows about ketamine for PTSD, with the aim of providing an honest, science-grounded picture of both the promise and the appropriate caution this field warrants.
Understanding PTSD: Why It Is So Hard to Treat
PTSD is more than a psychological response to a bad memory. It involves measurable changes in brain structure and function, neuroendocrine dysregulation, heightened immune activation, and alterations in how the nervous system processes threat. Neuroimaging research has documented differences in amygdala reactivity, prefrontal cortical function, and hippocampal volume in people with PTSD, findings that reflect the biological depth of the condition.
The core symptom clusters of PTSD, re-experiencing (flashbacks, nightmares, intrusive memories), avoidance of trauma-related cues, negative alterations in cognition and mood, and hyperarousal (hypervigilance, startle response, sleep disruption), interact and reinforce each other in ways that can make recovery difficult. Treatments that target one domain may leave others inadequately addressed. For some patients, the very process of engaging with trauma memories in standard trauma-focused therapy can be destabilizing enough to limit its effectiveness.
Standard Treatments for PTSD: What We Know
The most evidence-supported psychotherapies for PTSD are Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT), both of which are trauma-focused approaches recommended by major clinical guidelines including those from the VA/DoD and the American Psychological Association. EMDR (Eye Movement Desensitization and Reprocessing) also has substantial evidence. These therapies require patients to engage directly with traumatic material, and they are effective for many people.
On the medication side, sertraline and paroxetine are FDA-approved for PTSD. However, response rates are modest: approximately 60 percent of patients respond to first-line treatments, and remission is achieved by only about 20 to 30 percent. A large proportion of people with PTSD, particularly those with severe trauma histories or complex presentations, have persistent symptoms despite evidence-based care.
How Ketamine May Address the Neurobiology of PTSD
The glutamate system, which ketamine targets through NMDA receptor antagonism, plays a central role in fear memory formation, consolidation, and extinction. This is directly relevant to PTSD, which can be understood in part as a disorder of fear memory dysregulation: the brain’s normal process for distinguishing between threatening and safe situations becomes impaired, leading to persistent activation of threat-related responses.
Ketamine’s promotion of neuroplasticity, through rapid increases in BDNF and synaptic remodeling, may facilitate the kind of fear extinction that trauma-focused therapies aim to achieve. There is significant theoretical and emerging empirical support for the idea that ketamine could enhance the effectiveness of trauma-focused psychotherapy by creating a window of increased neural flexibility during which therapeutic work is more accessible. The combination of ketamine with psychotherapy, sometimes called ketamine-assisted psychotherapy (KAP), is an area of active clinical research and growing clinical interest.
What the Clinical Research Shows
Research on ketamine for PTSD is earlier-stage than the TRD literature but growing in both quantity and quality. A 2014 randomized controlled trial published in JAMA Psychiatry by Feder and colleagues at Mount Sinai demonstrated that a single infusion of ketamine produced significant reductions in PTSD symptom severity within 24 hours compared to midazolam control, with effects that were particularly pronounced in re-experiencing symptoms. Effect sizes were clinically meaningful, and the rapid onset is a distinctive feature compared to standard pharmacological approaches.
A subsequent randomized controlled trial by the same group, published in the American Journal of Psychiatry in 2021, confirmed the initial findings with a larger sample and repeated dosing, showing that multiple infusions produced greater and more sustained symptom reduction. Responders showed approximately 30 to 50 percent reductions in PTSD symptom scores, which is clinically significant in a population with chronic, treatment-resistant symptoms. Research is ongoing, and additional trials are examining optimal dosing protocols, the role of psychological support, and predictors of response.
PTSD and Comorbid Depression
PTSD and depression co-occur at high rates: approximately 50 percent of people with PTSD also meet criteria for major depressive disorder. This comorbidity complicates treatment because standard antidepressants may partially address depressive symptoms while leaving PTSD symptom clusters inadequately treated. Ketamine’s demonstrated efficacy across both conditions makes it potentially well-suited to complex presentations involving comorbid TRD and PTSD, though individualized clinical evaluation remains essential.
What Clinical Oversight Looks Like
Ketamine treatment for PTSD requires careful clinical oversight, including thorough evaluation of your trauma history and current symptom profile, screening for medical and psychiatric contraindications, discussion of what the treatment involves, and a plan for follow-up care. At Vantage Telehealth, this evaluation is conducted by licensed providers with appropriate clinical training. We take seriously the responsibility that comes with providing a controlled substance for mental health treatment, and we are committed to ensuring that any care you receive is individualized, carefully considered, and clinically appropriate.
If you are living with PTSD and have not found adequate relief through prior treatment, or if you are curious about what your options might be, we encourage you to begin with a clinical conversation. Our intake process is straightforward, confidential, and designed to be as low-barrier as possible. The first step is simply reaching out.
Learn more about ketamine-assisted therapy at Vantage
Frequently Asked Questions
Can ketamine therapy help PTSD symptoms?
Growing clinical evidence, including randomized trials, suggests that ketamine can reduce PTSD symptoms — particularly hyperarousal, intrusive thoughts, and emotional numbing — in some patients. Response is not universal and is typically strongest when ketamine is paired with structured therapy. It is one option among several evidence-based PTSD treatments.
How does ketamine treat PTSD?
Ketamine acts on the glutamate NMDA receptor system, which appears to promote synaptic plasticity — the brain’s ability to form new connections. This may open a window where trauma processing and integration in therapy become more effective. The mechanism differs from SSRIs, which act on serotonin.
What is the research on ketamine for PTSD?
Studies including work from Feder and colleagues have shown reductions in PTSD symptom scores following ketamine infusions in adults with chronic PTSD. Findings are promising but the evidence base is still developing, and researchers continue to study optimal dosing, frequency, and integration protocols. It is not yet a first-line treatment.
Is ketamine therapy safe for people with PTSD?
When delivered under clinical supervision with proper screening, low-dose ketamine has a well-characterized safety profile. Providers screen for contraindications including uncontrolled hypertension, active psychosis, and certain substance use histories. Vantage’s model includes provider evaluation, medical history review, and integration support.
How does ketamine compare to standard PTSD treatments?
Standard first-line PTSD treatments include trauma-focused therapies like prolonged exposure and cognitive processing therapy, and medications like sertraline or paroxetine. Ketamine is generally reserved for people who have not fully responded to these treatments. It can also work faster than SSRIs, which may take weeks.
Who is a candidate for ketamine therapy for PTSD?
Adults with a PTSD diagnosis who have not fully responded to trauma-focused therapy or first-line medications may be considered. Candidates must be medically screened, willing to participate in integration therapy, and free from disqualifying conditions. A licensed clinician in our partner medical network makes this determination during evaluation.
See how Vantage Telehealth can help — Get Started →
Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment recommendation. Ketamine is a Schedule III controlled substance and its use for mental health conditions must be supervised by a qualified medical provider. Clinical appropriateness for ketamine therapy is determined on an individual basis by your provider. If you are experiencing a mental health crisis or thoughts of suicide, please call or text 988 (Suicide and Crisis Lifeline), call 911, or go to your nearest emergency room. The information presented here reflects general educational content and may not apply to your specific situation. Always consult a licensed healthcare professional before starting any new treatment.